Ryan P. Terlecki, MD, FACS, presented “Optilume for BPH – Considerations for Use” during the 34th International Prostate Cancer Update on February 13, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Terlecki, Ryan P. “Optilume for BPH – Considerations for Use.” February 2024. Accessed Aug 2024. https://grandroundsinurology.com/optilume-for-bph-considerations-for-use/
Optilume for BPH – Considerations for Use – Summary
Ryan P. Terlecki, MD, FACS, examines the use of Optilume, a novel drug-coated balloon technology, in treating benign prostatic hyperplasia (BPH), focusing on its efficacy, safety, and clinical considerations.
He begins by explaining the mechanism of action of Optilume and reviews clinical trial data demonstrating its effectiveness in improving urinary flow rates and reducing symptom severity in patients with BPH. He highlights key findings, such as significant improvements in International Prostate Symptom Score (IPSS) and quality of life metrics, underscoring the potential of Optilume as an alternative to traditional BPH treatments like pharmacotherapy and surgical interventions.
He discusses patient selection criteria, potential contraindications, and the need for thorough patient evaluation before opting for this treatment. Dr. Terlecki delves into the procedural aspects of Optilume use, including technical considerations for optimal deployment and strategies to minimize complications.
Furthermore, Dr. Terlecki explores the comparative advantages of Optilume over existing BPH treatments and considers the economic implications.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Ryan P. Terlecki, MD, FACS, is a reconstructive urologist for Atrium Health Wake Forest Baptist Medical Center, an academic Level 1 trauma center in Winston-Salem, North Carolina. Dr. Terlecki holds the rank of Professor and the title of Vice Chair of Research for the Department of Urology. In addition, Dr. Terlecki is Director of the Men’s Health Clinic, Director of Medical Student Education, and Fellowship Director for Reconstructive Urology. He holds a joint appointment in the Department of Obstetrics and Gynecology.
Dr. Terlecki earned his medical degree from Wayne State University School of Medicine and completed residency in general surgery and urology at Detroit Medical Center. Following his residency, Dr. Terlecki completed two separate fellowships in reconstructive surgery. He completed a fellowship at the University of Colorado’s Denver School of Medicine and at UT Southwestern Medical Center in Dallas, Texas.
Dr. Terlecki’s publications cover multiple areas of trauma and reconstruction and his research is focused primarily on models of wound healing and regeneration in the lower genitourinary system. Dr. Terlecki’s areas of expertise include urethral stricture disease, male sexual dysfunction, male incontinence, Peyronie’s disease, chronic testicular pain, hypogonadism, and infertility. He is a member of the Society of Genitourinary Reconstructive Surgeons (GURS), a member of the American Urological Association (AUA), and past president of the North Carolina Urological Association (NCUA).
